title: Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?
authors: Department of Neurology, University of Rostock, Germany.
authors: D
authors: D
authors: Dressler
authors: U
authors: U
authors: Zettl
authors: R
authors: R
authors: Benecke
authors: H
authors: H
authors: Bigalke
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009465:Neuromuscular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014103:Torticollis / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D016756:Immunoglobulins, Intravenous; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A